biologic research and development centers of salubris are located in maryland, us, and chengdu and suzhou in china.

r&d platform of biological medicine

r&d platform for gene therapy drug

- an academic workstation specialized in the research and development of gene therapy drug established by salubris and national key laboratory of biotherapy (sklb).

- developing innovative gene therapy drugs for cancer and cerebrovascular disease with novel technologies such as tumor in situ vaccine, rna interference and gene editing.

r&d platform for antibody drug

- a comprehensive r&d platform for new antibody drugs, including monoclonal antibody, bifunctional antibody and antibody-drug conjugate, dedicated to develop the treatment of cerebrovascular disease, cancer, endocrine diseases, etc.

- with complete ability of antibody drug development including antibody molecule design, molecule screening and optimization, engineering cell line building, process developing, large-scale antibody production, antibody preparation development and quality standard establishment.

- with the support of the humanized antibody platform project and r&d and key innovative technology of new innovative antibody drug project started by ministry of health and ministry of science and technology.

r&d platform for recombinant protein drug

- have established a mature developing system of recombinant protein drug from gene cloning to new drug applying with several years experience of r&d.

achievements

20 understudied projects

11 new drugs projects

5 projects listed in china's 13th five-year plan for the creation of new drugs.

lyophilized recombinant human keratinocyte growth factor

- for severe oral mucositis and gastrointestinal mucositis caused by radiotherapy and chemotherapy in patients suffering from cancer.

recombinant sev-hfgf2/df injection

- the new medicine in gene therapy developed in cooperation with id pharma co., ltd, in japan.

- gene therapy project to start clinical trials, in synchronization with phase i clinical trials in china, phase ii clinical trials in japan and phase i clinical trials in australia.